Press coverage about Aralez Pharmaceuticals (NASDAQ:ARLZ) has been trending somewhat positive on Saturday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aralez Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.7018804493376 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities research analysts have recently commented on the company. HC Wainwright set a $6.00 price target on Aralez Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, March 15th. Bloom Burton lowered Aralez Pharmaceuticals from a “buy” rating to an “accumulate” rating in a research note on Wednesday, March 14th. Finally, Chardan Capital reissued a “buy” rating on shares of Aralez Pharmaceuticals in a research note on Tuesday, March 20th.
Shares of NASDAQ:ARLZ remained flat at $$1.39 during trading on Friday. The stock had a trading volume of 175,369 shares, compared to its average volume of 511,901. The stock has a market cap of $93.14, a price-to-earnings ratio of -1.16 and a beta of 1.59. The company has a debt-to-equity ratio of 18.05, a current ratio of 0.78 and a quick ratio of 0.68. Aralez Pharmaceuticals has a fifty-two week low of $0.95 and a fifty-two week high of $2.98.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings results on Tuesday, March 13th. The company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). Aralez Pharmaceuticals had a negative return on equity of 170.42% and a negative net margin of 118.18%. The firm had revenue of $28.02 million for the quarter, compared to analysts’ expectations of $25.75 million. sell-side analysts expect that Aralez Pharmaceuticals will post -0.66 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Aralez Pharmaceuticals (NASDAQ:ARLZ) Stock Price” was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://macondaily.com/2018/04/21/aralez-pharmaceuticals-arlz-getting-somewhat-positive-news-coverage-report-finds-updated.html.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.